

Gene expression profile of mesenchymal stromal cells after co-culturing with injured liver tissue

KYUNG-AH CHO¹, SUN-YOUNG JU¹, KYUNG-HA RYU² and SO-YOUN WOO¹

Departments of ¹Microbiology, and ²Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea

Received September 19, 2008; Accepted November 10, 2008

DOI: 10.3892/mmr_00000061

Abstract. Mesenchymal stromal cells (MSCs) are a potential cell source for the development of therapeutic products. Recent studies have shown that the transplantation of MSCs to damaged organs, including the heart, liver and kidneys, results in the restoration of the damaged tissues. However, the mechanisms underlying this regeneration process have yet to be clearly characterized. Consequently, in this study, we focused on the therapeutic potential of MSCs in injured liver tissue by evaluating the gene expression profiles of MSCs in the presence of injured liver and normal liver cells using a microarray chip containing 44,000 genes. In order to mimic the state of liver cell regeneration *in vitro*, we respectively co-cultured MSCs with CCl₄-injured liver cells and normal liver cells from C57BL/6 female mice. After 48 h of co-culturing, MSCs were collected and the RNA was extracted for microarray analysis. Under conditions of co-culture with normal liver cells, upregulated expression of CXCR6, CCR3, IL-2, IL-11, CD34, CD74, procollagen, FMS-like tyrosine kinase, neuregulin 4, Wnt2 and catenins was noted. Under conditions of co-culture with the CCl₄-injured liver cells, expression of CXCL2, cytoglobin, erythropoietin, v-Erb, hypoxia-inducible factor 3 (α subunit), retinoic acid receptor β and Vav2 was upregulated. Our research provides information regarding the differential molecular mechanisms that regulate the properties of MSCs in the regeneration of injured liver tissue.

Introduction

Bone marrow (BM) contains heterogenous cells consisting of hematopoietic stem cells (HSCs) and stromal cells, which support the development of HSCs. Among such cells, multipotent stromal cells, or mesenchymal stromal cells (MSCs), perform a supportive role as stromal cells in BM, and also possess the potential to differentiate into a variety of cell types, including osteocytes, chondrocytes, adipocytes

and neuronal cells. Recently, the differentiation of MSCs into hepatic cell lineages has been reported. This implies that MSCs might potentially be employed as a source of cell-based therapy for the purpose of tissue regeneration (1,2).

MSCs of this type residing in the BM can differentiate into hepatic cells, which express the liver-specific markers albumin, α -fetoprotein and cytokeratin 18 as a result of stimulation with stem cell factor, epidermal growth factor and hepatocyte growth factor (3). MSCs can also be differentiated into hepatic lineage cells by co-culturing with liver tissues. In previous studies, MSCs were co-cultured with fetal liver cells (1) or liver cells, and were shown to differentiate into functional liver cells secreting albumin and urea after 48 h of co-culture (2).

We previously reported that BM cells ameliorate the pathologic conditions of CCl₄-induced liver injury in mice (4). As MSCs derived from BM are one source of stem cells toward hepatic lineage, they principally differentiate into functional hepatocytes and may contribute to the regeneration of injured liver tissues. Therefore, we analyzed the gene expression profile of MSCs co-cultured with liver cells that mimicked the liver microenvironment *in vitro*. The gene expression profiles of MSCs were assessed after co-culturing with normal liver cells or with liver cells from CCl₄-injected mice via a microarray technique.

Materials and methods

Mice. Six-week-old C57BL/6 mice were purchased from Koatec (Pyung-Taek, Korea). All mice were bred and housed under specific pathogen-free conditions. All procedures were approved by the Animal Care and Use Committee of the Ewha Womans University School of Medicine.

Cell culture

Isolation and culture of MSCs. Six- to eight-week-old C57BL/6 female mice were sacrificed by cervical dislocation and their limbs were removed. The BM was flushed from the medullary cavities of both the femurs and tibias with serum-free RPMI-1640 medium (Gibco BRL, Carlsbad, CA) using a 25-gauge needle, filtrated through nylon meshes and centrifugated for 5 min at 1,200 rpm. Isolated BM cells were then incubated in RBC lysis solution (0.15 M NH₄Cl, 10 mM NaHCO₃, 10 mM EDTA) and washed twice with phosphate-buffered saline (PBS). The cells were then plated at 1x10⁷ cells/100 culture dishes in Iscove's Modified Dulbecco's Medium (IMDM; Sigma, St. Louis, MO) with 10% heat-inactivated

Correspondence to: Dr So-Youn Woo, Department of Microbiology, School of Medicine, Ewha Womans University, 911-1 Mok-6-Dong, Yang-chun-gu, 158-710 Seoul, Korea
E-mail: soyounwoo@ewha.ac.kr

Key words: mesenchymal stromal cells, liver injury, microarray, gene expression

fetal bovine serum (FBS). After 48 h, non-adherent cells were removed via aspiration, and the Mesencult basal medium with 10% mesenchymal stem cell stimulatory supplement (Stem Cell Technologies, Vancouver, Canada; cat. nos. 05501 and 05502) was replenished. Three weeks from the BM isolation, all MSCs used in this study were at 4 passages.

Adipogenic differentiation. MSCs cultured for 3 weeks following primary culture were plated on Mesencult basal medium containing 10% adipogenic stimulatory supplement (Stem Cellfigl Technologies; cat. no. 05401). The medium was replenished once every 3 days for 2 weeks.

Liver cell isolation. Six-week-old mice were injected once a day with 10% CCl₄ (10 μ l per gram) in mineral oil via the intraperitoneal route for two consecutive days. After 1 week, the mice were sacrificed and their liver tissues were collected aseptically followed by 30 min of collagenase treatment (0.5 mg/ml in RPMI-1640 with 10% FBS; Roche, Indianapolis, IN) at 37°C. Liver cells were isolated from the collagenase-treated liver tissue following filtration through nylon meshes. For the co-culturing of liver cells and MSCs, the MSCs (5x10⁵ cells/well) were plated onto the lower chambers of transwell culture plates (Falcon, Bedford, MA), while the liver cells (3x10⁵/well) were introduced into the inserted upper-chamber (3 μ m in pore size) with Dulbecco's modified Eagle's medium (Fig. 1H). After 48 h of co-culture, the inserted upper chambers were removed, and the MSCs in the lower chamber were collected for RNA isolation.

Flow cytometry. MSCs were analyzed for cell surface marker expression after culturing for 3 weeks. The cells were washed with PBS and stained at 4°C for 30 min with a combination of the following antibodies: FITC-anti-mouse CD106, FITC-anti-mouse CD34, FITC-anti-mouse CD31, PE-anti-mouse CD73, PE-anti-mouse CD105, PE-anti-mouse CD45. All antibodies were purchased from BD Pharmingen with the exception of PE-anti-mouse CD105, which was obtained from R&D Systems (Minneapolis, MN). Flow cytometric analysis was performed using FACSCalibur and CellQuest software (BD).

Tissue preparation. The liver was perfused via the heart with 4% paraformaldehyde to flush out blood cells, then incubated with 4% paraformaldehyde overnight at room temperature for fixation. After washing twice with water, fixed livers were stored in 70% ethanol at 4°C and embedded in paraffin. Sections were stained with hematoxylin and eosin.

Cell staining

Albumin staining. MSCs co-cultured with liver cells or not, as described above, were fixed for 10 min in ice-cold methanol. The cells were treated with 1% BSA in PBST (0.05% Tween-20 in PBS) for 30 min to block the unspecific binding of antibodies, then incubated overnight in primary antibody against albumin (Abcam; cat. no. ab19196) at 4°C (1:800). The next day, the secondary antibody, biotinylated anti-rabbit IgG (DakoCytomation, Denmark) was applied for 30 min. Albumin expression was detected via the streptavidin-HRP/DAB substrate (DakoCytomation) reaction.

Giemsa staining. After 14 days of MSC culture, colony forming units of fibroblasts (CFU-F) were assessed after Giemsa staining. Cells fixed in methanol for 5 min were completely dried, and Giemsa stain solution was added.

Adipocyte staining. Adipocytes differentiated from MSCs were stained with Oil Red O solution. First, the cells were fixed for 5 min in 10% formalin and incubated for 1 h in newly changed 10% formalin. After washing with 60% isopropanol, the cells were dried completely and treated for 1 h with Oil Red O solution.

Isolation of total RNA. Total RNA was extracted from adherent MSCs co-cultured with normal liver tissue or liver tissue from CCl₄-injected mice, as well as from MSCs without co-culture, using TRIzol solution (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's instructions. RNA samples were stored at -70°C until future use.

Microarray analysis. Two-color microarray-based Agilent chips containing 44,000 mouse genes (Digital Genomics, Seoul, Korea) were utilized. Total RNA (50 μ g) was prepared from 3 groups of MSCs: the MSC group (untreated MSCs), the liver group (from MSCs co-cultured with normal liver cells) and the CCl₄ liver group (from MSCs co-cultured with the livers of CCl₄-injected mice). Samples from the MSC group were labeled with Cy5 while samples from the liver group were labeled with Cy3, and RNA samples from the MSC group were utilized as RNA references for the comparison of gene expression profiles. These microarray experiments were repeated three times for the different RNA batches. Genes were selected on the basis of differential Cy3/Cy5 expression ratios ≥ 2 in response. Gene clustering was generated from the gene expression data using Cluster and TreeView software (Eisen Lab; <http://rana.lbl.gov/EisenSoftware.htm>). Additional filtering was applied with a 2-fold change minimum to analyze the genes expressed in mouse liver tissue using Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA; <http://www.ingenuity.com/>).

Results

Before the liver cells from CCl₄-injected mice were isolated, liver tissue from the normal (control) and CCl₄-injected mice was fixed and stained with H&E (Fig. 1) so that differences between the two groups might be examined. Fig. 1A and B show characteristic features of the mouse liver, such as anisocytosis (an uneven size of liver cells) and anisokaryosis (an uneven size of liver cell nuclei). In Fig. 1B, a liver section from a CCl₄-injected mouse exhibits vacuolization of the liver cells, indicating that the cells were damaged by the CCl₄ injection.

In order to characterize the MSCs from the liver group, a CFU-F assay was performed (Fig. 2B) and the isolated MSCs were induced to differentiate into adipocytes (Fig. 2C) to confirm their multipotential differentiation. Additionally, CD73, CD105 and CD106 expression, as well as the negative expression of CD31, CD34 and CD45, was observed (Fig. 2D).

To assess the gene expression profiles of the MSCs from the liver and CCl₄ liver groups, we co-cultured liver cells in the upper chamber and MSCs in the lower chamber of transwell plates (Fig. 3). After 48 h of transwell culture, the upper chamber was removed and the cells from the lower chamber, containing MSCs stimulated by liver cells or injured liver cells, were collected. Next, RNAs from the cells of the lower chamber were isolated. Co-culture and RNA isolation was




Figure 1. Representative sections of liver tissue stained with hematoxylin and eosin. (A) Normal liver. (B) Injured liver from a mouse 8 days after 2 consecutive injections of CCl_4 . White punctuated space among the liver cells from CCl_4 -injected mice can be seen. (Original magnification, $\times 200$).

repeated three times for each of the experimental groups, and the expression profile was presented as the mean values from these three microchip assay analyses.

Genes upregulated in the liver group as compared with the untreated MSC group are listed in Table I. Genes upregulated in the CCl_4 liver group as compared with the MSC group are shown in Table II. In addition, Tables III and IV show IPA-filtered genes that evidenced a >2 -fold change in the gene expression of MSCs from the liver and CCl_4 liver groups, respectively. The results of microarray analysis of MSCs from the liver group demonstrate that inhibitor of DNA binding 1, Forkhead box G1, Wnt2, CD34, CXCR6 (receptor for CXCL16), tissue inhibitor of metalloproteinase 3, periostin, procollagen type 1, IL-2, neuregulin 4, CCR3 (receptor for RANTES, MCP-2, -3, -4), IL-11, CD74 (Ii chain of class II MHC molecules) and catenins were upregulated. When co-cultured with the CCl_4 -injured liver cells, the expression of RAR-related orphan receptor β , retinoic acid receptor β , forkhead box G1, neural cell adhesion molecule 1, matrix metalloproteinase 12, insulin-like growth factor binding protein 6, nerve growth factor receptor, chordin, CXCL2, cytoglobin, erythropoietin, v-Erb, hypoxia inducible factor 3 (α subunit), Vav2 and hepatic nuclear factor 4 α was upregulated.

Immunostaining analysis of albumin was conducted on MSCs co-cultured with liver cells from mice treated or untreated with CCl_4 . After 48 h of co-culture with CCl_4 -treated liver cells, the MSCs expressed albumin (Fig. 4). Therefore, MSCs derived from BM cells seemed to differentiate into functional hepatocytes under the specific conditions provided by a damaged liver.




Figure 2. Preparation and characterization of isolated MSCs. The newly planted bone marrow cells were divided into adherent and non-adherent cells after 48 h of culture. (A) Adherent cells, or MSCs, proliferated and formed CFU-F. (B) This was confirmed by Giemsa staining on day 14. (C) MSCs cultured for 3 weeks were differentiated into adipocytes and stained red with Oil Red O (original magnification A-C, $\times 100$). (D) For the phenotypic markers, the MSC markers (CD73, CD105 and CD106) were positive. In contrast, the hematopoietic (CD34 and CD45) and endothelial (CD31) cell markers were not detectable in the cells after 21 days of culture.




Figure 3. Co-culturing of MSCs and liver cells in transwell plates. (A) MSCs and injured livers were established according to the indicated co-culture schedule. (B) MSCs co-cultured with normal or CCl_4 -injured liver cells on the transwell insert co-culture system.




Figure 4. Albumin detection in co-cultured MSCs by immunocytochemistry. MSCs cultured alone (A) or co-cultured with normal liver cells (B) did not express albumin. However, MSCs co-cultured with CCl_4 -injected liver cells (C) evidenced albumin positivity.

Table I. Genes upregulated in MSCs co-cultured with normal liver cells.

Accession	Symbol	Name	Mean
NM_207624	<i>ACE</i>	Mus musculus angiotensin converting enzyme (Ace), transcript variant 1, mRNA [NM_207624]	2.21
NM_007392	<i>ACTA2</i>	Actin, $\alpha 2$, smooth muscle, aorta	2.64
NM_007395	<i>ACVR1B</i>	Activin A receptor, type 1B	2.09
NM_009633	<i>ADRA2B</i>	Adrenergic receptor, $\alpha 2b$	2.78
NM_011784	<i>AGTRL1</i>	Angiotensin receptor-like 1	2.59
NM_011784	<i>AGTRL1</i>	Angiotensin receptor-like 1	2.34
NM_009914	<i>CCR3</i>	Chemokine (C-C motif) receptor 3	2.08
NM_133654	<i>CD34</i>	CD34 antigen	4.22
NM_010545	<i>CD74</i>	CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	2.19
NM_007664	<i>CDH2</i>	Cadherin 2	2.01
NM_007664	<i>CDH2</i>	Cadherin 2	2.01
NM_007693	<i>CHGA</i>	Chromogranin A	2.31
NM_016673	<i>CNTFR</i>	Ciliary neurotrophic factor receptor	2.84
NM_007742	<i>COL1A1</i>	Procollagen, type I, $\alpha 1$	3.22
NM_007743	<i>COL1A2</i>	Procollagen, type I, $\alpha 2$	2.14
AK076297	<i>COL27A1</i>	Procollagen, type XXVII, $\alpha 1$	2.27
AK008121	<i>CTNNA1</i>	Catenin (cadherin associated protein), $\alpha 1$	2.41
AK077879	<i>CTNNAL1</i>	Catenin (cadherin associated protein), $\beta 1$	2.92
NM_030712	<i>CXCR6</i>	Chemokine (C-X-C motif) receptor 6	3.40
NM_030206	<i>CYGB</i>	Mus musculus cytoglobin	2.49
NM_009998	<i>CYP2B10</i>	Cytochrome P450, family 2, subfamily b, polypeptide 10	2.03
NM_007822	<i>CYP4A14</i>	Cytochrome P450, family 4, subfamily a, polypeptide 14	2.32
NM_007824	<i>CYP7A1</i>	Cytochrome P450, family 7, subfamily a, polypeptide 1	2.04
NM_010045	<i>DARC</i>	Duffy blood group, chemokine receptor	2.52
NM_010106	<i>EEF1A1</i>	Eukaryotic translation elongation factor 1 $\alpha 1$	2.12
NM_010109	<i>EFNA5</i>	Ephrin A5	2.13
NM_207667	<i>FGF14</i>	Fibroblast growth factor 15	2.04
NM_008005	<i>FGF18</i>	Fibroblast growth factor 2	2.44
AK005502	<i>FLT1</i>	FMS-like tyrosine kinase 1	2.06
AK034946	<i>FMO1</i>	Flavin containing monooxygenase 1	2.13
NM_008241	<i>FOXG1</i>	Forkhead box G1	4.55
NM_008126	<i>GJB3</i>	Gap junction membrane channel protein $\beta 3$	2.80
NM_008127	<i>GJB4</i>	Gap junction membrane channel protein $\beta 4$	2.44
NM_013920	<i>HNF4G</i>	Hepatocyte nuclear factor 4, γ	2.55
NM_008296	<i>HSF1</i>	Heat shock factor 1	2.53
NM_010495	<i>ID1</i>	Inhibitor of DNA binding 1	4.69
NM_008344	<i>IGFBP6</i>	Insulin-like growth factor binding protein 6	3.19
NM_008350	<i>IL-11</i>	Interleukin 11	3.13
NM_019451	<i>IL-1F5</i>	Interleukin 1 family, member 5 (δ)	2.45
NM_008366	<i>IL-2</i>	Interleukin 2	3.20
NM_008368	<i>IL-2RB</i>	Interleukin 2 receptor, β chain	3.03
NM_013565	<i>ITGA3</i>	Integrin $\alpha 3$	2.00
NM_008501	<i>LIF</i>	Leukemia inhibitory factor	2.32
NM_009158	<i>MAPK10</i>	Mitogen activated protein kinase 10	2.08
NM_008598	<i>MGMT</i>	O-6-methylguanine-DNA methyltransferase	2.03
NM_011846	<i>MMP17</i>	Matrix metalloproteinase 17	2.14
NM_010808	<i>MMP24</i>	Matrix metalloproteinase 24	2.01
AK038264	<i>MSH3</i>	MutS homolog 3 (<i>E. coli</i>)	2.36
NM_008634	<i>MTAP1B</i>	Microtubule-associated protein 1 B	2.37
NM_013607	<i>MYH11</i>	Myosin, heavy polypeptide 11, smooth muscle	2.21
NM_013607	<i>MYH11</i>	Myosin, heavy polypeptide 11, smooth muscle	2.21

Table I. Continued.

Accession	Symbol	Name	Mean
X15052	<i>NCAM1</i>	Neural cell adhesion molecule 1	2.25
NM_010875	<i>NCAM1</i>	Neural cell adhesion molecule 1	2.14
NM_010900	<i>NFATC2IP</i>	Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein	2.10
NM_008700	<i>NKX2-5</i>	NK2 transcription factor related, locus 5 (<i>Drosophila</i>)	2.60
AK012322	<i>NR2F2</i>	Nuclear receptor subfamily 2, group F, member 2	2.91
X76653	<i>NR2F2</i>	Nuclear receptor subfamily 2, group F, member 2	2.40
NM_032002	<i>NRG4</i>	Neuregulin 4	3.19
NM_008814	<i>PDX1</i>	Pancreatic and duodenal homeobox 1	2.30
NM_015784	<i>POSTN</i>	Periostin, osteoblast specific factor	3.28
NM_008969	<i>PTGS1</i>	Prostaglandin-endoperoxide synthase 1	2.31
NM_008973	<i>PTN</i>	Pleiotrophin	2.76
NM_011243	<i>RARB</i>	Retinoic acid receptor, β	3.06
NM_009084	<i>RPL37A</i>	Ribosomal protein L37a	2.10
NM_009115	<i>S100B</i>	S100 protein, β polypeptide, neural	2.55
NM_011347	<i>SELP</i>	Selectin, platelet	2.07
AK038807	<i>SLIT2</i>	slit homolog 2 (<i>Drosophila</i>)	2.20
AK020817	<i>SMUG1</i>	Single-strand selective monofunctional uracil DNA glycosylase	2.14
NM_009235	<i>SOX15</i>	SRY-box containing gene 15	2.00
NM_011443	<i>SOX2</i>	SRY-box containing gene 2	2.56
NM_025285	<i>STMN2</i>	Stathmin-like 2	3.03
NM_019507	<i>TBX21</i>	T-box 21	2.20
NM_011595	<i>TIMP3</i>	Tissue inhibitor of metalloproteinase 3	3.31
NM_021406	<i>TREM1</i>	Triggering receptor expressed on myeloid cells 1	2.22
AK048623	<i>TRP63</i>	Transformation related protein 63	2.19
AK006986	<i>TYK2</i>	Tyrosine kinase 2	2.70
NM_011707	<i>VTN</i>	Vitronectin	2.07
NM_023653	<i>WNT2</i>	Wingless-related MMTV integration site 2	4.22
NM_009523	<i>WNT4</i>	Wingless-related MMTV integration site 4	2.56

Table II. Genes upregulated in MSCs co-cultured with CCl₄-injured liver cells.

Accession	Symbol	Name	Mean
AK051467	<i>AGTPBP1</i>	ATP/GTP binding protein 1	2.07
NM_011784	<i>AGTRL1</i>	Angiotensin receptor-like 1	2.33
NM_019577	<i>CCL24</i>	Chemokine (C-C motif) ligand 24	2.37
NM_009139	<i>CCL6</i>	Chemokine (C-C motif) ligand 6	2.26
NM_133654	<i>CD34</i>	CD34 antigen	2.56
NM_007650	<i>CD5</i>	CD5 antigen	2.33
NM_009873	<i>CDK6</i>	Cyclin-dependent kinase 6	2.80
NM_009893	<i>CHRD</i>	Chordin	3.08
AK003879	<i>COL27A1</i>	Procollagen, type XXVII, α 1	2.57
NM_007758	<i>CR2</i>	Complement receptor 2	2.39
NM_008176	<i>CXCL2</i>	Chemokine (C-X-C motif) ligand 2	2.60
NM_030206	<i>CYGB</i>	Cytoglobin	4.90
NM_201640	<i>CYP4A10</i>	Cytochrome P450, family 4, subfamily a, polypeptide 10	2.09
NM_007824	<i>CYP7A1</i>	Cytochrome P450, family 7, subfamily a, polypeptide 1	2.29
AK009701	<i>DAPK1</i>	Death associated protein kinase 1	2.08
NM_010109	<i>EFNA5</i>	Ephrin A5	2.04
NM_207655	<i>EGFR</i>	Epidermal growth factor receptor	2.23

Table II. Continued.

Accession	Symbol	Name	Mean
NM_007942	<i>EPO</i>	Erythropoietin	2.73
XM_136682	<i>ERBB4</i>	v-Erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)	2.46
NM_021272	<i>FABP7</i>	Fibroblast growth factor 1	2.22
NM_207667	<i>FGF14</i>	Fibroblast growth factor 15	2.42
NM_008005	<i>FGF18</i>	Fibroblast growth factor 2	2.90
AK008922	<i>FGF22</i>	Fibroblast growth factor 23	2.32
NM_008011	<i>FGFR4</i>	Fibroblast growth factor receptor 4	2.17
NM_008241	<i>FOXP1</i>	Forkhead box G1	3.46
NM_008055	<i>FZD4</i>	Frizzled homolog 4 (<i>Drosophila</i>)	2.52
NM_008107	<i>GDF1</i>	Growth differentiation factor 1	2.06
NM_008160	<i>GPX1</i>	Glutathione peroxidase	2.06
AK002213	<i>GSTM1</i>	Glutathione S-transferase, mu 1	2.63
NM_016868	<i>HIF3A</i>	Hypoxia inducible factor 3, α subunit	2.22
NM_008261	<i>HNF4A</i>	Hepatic nuclear factor 4, α	3.03
NM_010495	<i>ID1</i>	Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein	2.11
NM_010496	<i>ID2</i>	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	2.10
NM_008344	<i>IGFBP6</i>	Insulin-like growth factor binding protein 6	3.18
NM_019451	<i>IL1F5</i>	Interleukin 1 family, member 5 (δ)	2.37
NM_001005608	<i>ITGB4</i>	Integrin β 4	2.00
XM_140451	<i>LAMA3</i>	Laminin, α 3	2.27
BC070467	<i>MAP2K7</i>	Mitogen activated protein kinase kinase 7	2.02
AK053819	<i>MAPK8IP1</i>	Mitogen activated protein kinase 8 interacting protein 1	2.30
NM_008605	<i>MMP12</i>	Matrix metalloproteinase 12	3.34
NM_008611	<i>MMP8</i>	Matrix metalloproteinase 8	2.22
NM_133250	<i>MUTYH</i>	MutY homolog (<i>E. coli</i>)	2.06
AK048336	<i>MYST4</i>	MYST histone acetyltransferase monocytic leukemia 4	2.08
X15052	<i>NCAM1</i>	Neural cell adhesion molecule 1	3.36
NM_010896	<i>NEUROG1</i>	Neurogenin 1	2.14
NM_033217	<i>NGFR</i>	Nerve growth factor receptor (TNFR superfamily, member 16)	3.11
NM_008725	<i>NPPA</i>	Natriuretic peptide precursor type A	2.49
AK041047	<i>NR1D1</i>	Nuclear receptor subfamily 1, group D, member 1	2.22
X76653	<i>NR2F2</i>	Nuclear receptor subfamily 2, group F, member 2	2.61
AK012322	<i>NR2F2</i>	Nuclear receptor subfamily 2, group F, member 2	2.58
NM_013630	<i>PKD1</i>	Polycystic kidney disease 1 homolog	2.09
AK040305	<i>POL1</i>	Polymerase (DNA directed), α	2.00
BC042707	<i>PROK1</i>	Prokineticin 1	2.37
NM_008973	<i>PTN</i>	Pleiotrophin	2.54
NM_011243	<i>RARB</i>	Retinoic acid receptor, β	4.88
NM_011244	<i>RARG</i>	Retinoic acid receptor, γ	2.05
NM_134257	<i>RGS3</i>	Regulator of G-protein signaling 3	2.09
BC058269	<i>RORB</i>	RAR-related orphan receptor β	5.32
NM_009115	<i>S100B</i>	S100 protein, β polypeptide, neural	2.31
AK038807	<i>SLIT2</i>	slit homolog 2 (<i>Drosophila</i>)	3.00
AK090367	<i>SMUG1</i>	Single-strand selective monofunctional uracil DNA glycosylase	2.56
NM_011445	<i>SOX6</i>	SRY-box containing gene 6	2.93
NM_011448	<i>SOX9</i>	SRY-box containing gene 9	2.73
NM_009291	<i>STRA6</i>	Stimulated by retinoic acid gene 6	2.21
NM_011578	<i>TGFBR3</i>	Transforming growth factor, β receptor III	2.00
NM_009380	<i>THRB</i>	Thyroid hormone receptor β	2.95
AK006986	<i>TYK2</i>	Tyrosine kinase 2	2.46
NM_009500	<i>VAV2</i>	Vav 2 oncogene	2.14
M89800	<i>WNT6</i>	Wingless-related MMTV integration site 6	2.34

Table III. Gene expression profiles in MSCs co-cultured with normal liver cells.

Symbol	Name	Location	Accession	Fold change
<i>ACE</i>	Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Plasma membrane	NM_207624	2.206
<i>ACTA2</i> (includes EG:59)	Actin, $\alpha 2$, smooth muscle, aorta	Cytoplasm	NM_007392	2.642
<i>ACVR1B</i>	Activin A receptor, type IB	Plasma membrane	NM_007395	2.092
<i>ADAMTS1</i>	ADAM metalloproteinase with thrombospondin type 1 motif, 1	Extracellular space	NM_009621	-3.448
<i>ADAMTS5</i>	ADAM metalloproteinase with thrombospondin type 1 motif, 5 (aggrecanase-2)	Extracellular space	AK046558	-3.19
<i>APAF1</i>	Apoptotic peptidase activating factor 1	Cytoplasm	NM_009684	-2.001
<i>BCL10</i>	B-cell CLL/lymphoma 10	Cytoplasm	AK080820	-2.157
<i>BCL2L11</i>	BCL2-like 11 (apoptosis facilitator)	Cytoplasm	NM_207680	-2.062
<i>C3</i>	Complement component 3	Extracellular space	NM_009778	-6.849
<i>CASP3</i>	Caspase 3, apoptosis-related cysteine peptidase	Cytoplasm	NM_009810	-2.423
<i>CAV1</i>	Caveolin 1, caveolae protein, 22 kDa	Plasma membrane	NM_007616	-2.479
<i>CD34</i>	CD34 molecule	Plasma membrane	NM_133654	4.217
<i>CD36</i>	CD36 molecule (thrombospondin receptor)	Plasma membrane	NM_007643	-2.174
<i>CD74</i>	CD74 molecule, major histocompatibility complex, class II invariant chain	Plasma membrane	NM_010545	2.192
<i>CD86</i>	CD86 molecule	Plasma membrane	NM_019388	-2.618
<i>CDC42</i>	Cell division cycle 42 (GTP binding protein, 25 kDa)	Cytoplasm	NM_009861	-2.217
<i>CDH2</i>	Cadherin 2, type 1, N-cadherin (neuronal)	Plasma membrane	NM_007664	2.012
<i>CEACAM1</i>	Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)	Plasma membrane	NM_011926	-2.506
<i>CFLAR</i>	CASP8 and FADD-like apoptosis regulator	Cytoplasm	NM_009805	-2.389
<i>CNTFR</i>	Ciliary neurotrophic factor receptor	Plasma membrane	NM_016673	2.836
<i>COL18A1</i>	Collagen, type XVIII, $\alpha 1$	Extracellular space	NM_009929	-2.326
<i>COL1A1</i>	Collagen, type I, $\alpha 1$	Extracellular space	NM_007742	3.218
<i>COL1A2</i>	Collagen, type I, $\alpha 2$	Extracellular space	NM_007743	2.143
<i>COL27A1</i>	Collagen, type XXVII, $\alpha 1$	Extracellular space	AK076297	2.270
<i>CUL1</i>	Cullin 1	Nucleus	NM_012042	-3.055
<i>CXCL3</i>	Chemokine (C-X-C motif) ligand 3	Extracellular space	NM_009140	-2.439
<i>CXCL12</i>	Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)	Extracellular space	NM_013655	-2.329
<i>CXCR6</i> (includes EG:10663)	Chemokine (C-X-C motif) receptor 6	Plasma membrane	NM_030712	3.400
<i>CYP2B6</i> (includes EG:1555)	Cytochrome P450, family 2, subfamily B, polypeptide 6	Cytoplasm	NM_009998	2.027
<i>EEF1A1</i>	Eukaryotic translation elongation factor 1 $\alpha 1$	Cytoplasm	NM_010106	2.120
<i>EFNA5</i>	Ephrin-A5	Plasma membrane	NM_010109	2.130
<i>ERBB2IP</i>	erbB2 interacting protein	Extracellular space	NM_001005868	-2.107
<i>FN1</i>	Fibronectin 1	Plasma membrane	NM_010233	-2.439
<i>GNAI3</i>	Guanine nucleotide binding protein (G protein), $\alpha 13$	Plasma membrane	NM_010303	-2.128
<i>HGF</i>	Hepatocyte growth factor (hepapoietin A; scatter factor)	Extracellular space	NM_010427	-2.439
<i>ID1</i>	Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein	Nucleus	NM_010495	4.690
<i>IGF2</i>	Insulin-like growth factor 2 (somatomedin A)	Extracellular space	NM_010514	-2.528
<i>IGFBP6</i>	Insulin-like growth factor binding protein 6	Extracellular space	NM_008344	3.192
<i>IL1B</i>	Interleukin 1, β	Extracellular space	NM_008361	-3.906
<i>IL1RN</i>	Interleukin 1 receptor antagonist	Extracellular space	NM_031167	-2.924

Table III. Continued.

Symbol	Name	Location	Accession	Fold change
<i>ITGA3</i>	Integrin, $\alpha 3$ (antigen CD49C, $\alpha 3$ subunit of VLA-3 receptor)	Plasma membrane	NM_013565	2.002
<i>ITGA6</i>	Integrin, $\alpha 6$	Plasma membrane	AK045391	-2.551
<i>KITLG</i> (includes EG:4254)	KIT ligand	Extracellular space	NM_013598	-2.171
<i>MAF</i>	v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)	Nucleus	NM_001025577	-2.309
<i>MAPK9</i>	Mitogen-activated protein kinase 9	Cytoplasm	NM_207692	-2.003
<i>MCL1</i>	Myeloid cell leukemia sequence 1 (BCL2-related)	Cytoplasm	NM_008562	-2.547
<i>MMP17</i>	Matrix metalloproteinase 17 (membrane-inserted)	Extracellular space	NM_011846	2.142
<i>MMP24</i>	Matrix metalloproteinase 24 (membrane-inserted)	Extracellular space	NM_010808	2.012
<i>NFATC2</i>	Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2	Nucleus	AK081853	-2.237
<i>NR3C1</i>	Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)	Nucleus	NM_008173	-2.134
<i>PTGS1</i>	Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	Cytoplasm	NM_008969	2.310
<i>PTPRC</i>	Protein tyrosine phosphatase, receptor type, C	Plasma membrane	NM_011210	-3.067
<i>PTX3</i>	Pentraxin-related gene, rapidly induced by IL-1 β	Extracellular space	NM_008987	-2.182
<i>RARB</i>	Retinoic acid receptor, β	Nucleus	NM_011243	3.058
<i>SELP</i>	Selectin P (granule membrane protein 140 kDa, antigen CD62)	Plasma membrane	NM_011347	2.070
<i>SLIT2</i>	Slit homolog 2 (<i>Drosophila</i>)	Extracellular space	AK038807	2.200
<i>SOCS3</i>	Suppressor of cytokine signaling 3	Cytoplasm	NM_007707	-2.268
<i>SPP1</i>	Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)	Extracellular space	NM_009263	-2.060
<i>TNFRSF9</i>	Tumor necrosis factor receptor superfamily, member 9	Plasma membrane	AK019885	-2.000
<i>TNFRSF11B</i>	Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Plasma membrane	NM_008764	-2.538
<i>UBA1</i>	Ubiquitin-like modifier activating enzyme 1	Cytoplasm	NM_009457	-2.660
<i>VTN</i>	Vitronectin	Extracellular space	NM_011707	2.070

Table IV. Gene expression profiles in MSCs co-cultured with CCl₄-injured liver cells.

Symbol	Name	Location	Accession	Fold Change
<i>ADAMTS1</i>	ADAM metalloproteinase with thrombospondin type 1 motif, 1	Extracellular space	NM_009621	-3.724
<i>ADAMTS5</i>	ADAM metalloproteinase with thrombospondin type 1 motif, 5 (aggrecanase-2)	Extracellular space	AK046558	-4.255
<i>AHR</i>	Aryl hydrocarbon receptor	Nucleus	NM_013464	-2.930
<i>AKT1</i>	v-akt murine thymoma viral oncogene homolog 1	Cytoplasm	NM_009652	-2.083
<i>APAF1</i>	Apoptotic peptidase activating factor 1	Cytoplasm	NM_009684	-2.209
<i>BCL10</i>	B-cell CLL/lymphoma 10	Cytoplasm	AK080820	-2.532
<i>C3</i>	Complement component 3	Extracellular space	NM_009778	-4.415
<i>CASP3</i>	Caspase 3, apoptosis-related cysteine peptidase	Cytoplasm	NM_009810	-2.597
<i>CASP4</i>	Caspase 4, apoptosis-related cysteine peptidase	Cytoplasm	NM_007609	-2.360
<i>CAV1</i>	Caveolin 1, caveolae protein, 22 kDa	Plasma membrane	NM_007616	-2.297
<i>CCL24</i>	Chemokine (C-C motif) ligand 24	Extracellular space	NM_019577	2.368
<i>CCRL1</i>	Chemokine (C-C motif) receptor-like 1	Plasma membrane	NM_145700	-2.060
<i>CD5</i>	CD5 molecule	Plasma membrane	NM_007650	2.327
<i>CD34</i>	CD34 molecule	Plasma membrane	NM_133654	2.561
<i>CD86</i>	CD86 molecule	Plasma membrane	NM_019388	-2.558

Table IV. Continued.

Symbol	Name	Location	Accession	Fold Change
<i>CDK2</i>	Cyclin-dependent kinase 2	Nucleus	NM_183417	-2.091
<i>CFLAR</i>	CASP8 and FADD-like apoptosis regulator	Cytoplasm	NM_207653	-2.498
<i>COL18A1</i>	Collagen, type XVIII, $\alpha 1$	Extracellular space	NM_009929	-2.239
<i>COL27A1</i>	Collagen, type XXVII, $\alpha 1$	Extracellular space	AK003879	2.572
<i>CUL1</i>	Cullin 1	Nucleus	NM_012042	-2.727
<i>CXCL2</i>	Chemokine (C-X-C motif) ligand 2	Extracellular space	NM_008176	2.600
<i>CXCL10</i>	Chemokine (C-X-C motif) ligand 10	Extracellular space	NM_021274	-3.448
<i>EFNA5</i>	Ephrin-A5	Plasma membrane	NM_010109	2.040
<i>EGFR</i>	Epidermal growth factor receptor [erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian]	Plasma membrane	NM_207655	2.230
<i>ERBB2IP</i>	erbB2 interacting protein	Extracellular space	NM_001005868	-2.089
<i>GNA13</i>	Guanine nucleotide binding protein (G protein), $\alpha 13$	Plasma membrane	NM_010303	-2.083
<i>GPX1</i>	Glutathione peroxidase 1	Cytoplasm	NM_008160	2.063
<i>HGF</i>	Hepatocyte growth factor (hepapoietin A; scatter factor)	Extracellular space	NM_010427	-2.222
<i>HNF4A</i>	Hepatocyte nuclear factor 4, α	Nucleus	NM_008261	2.144
<i>ID1</i>	Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein	Nucleus	NM_010495	2.113
<i>ID2</i>	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	Nucleus	NM_010496	2.095
<i>IGF2</i>	Insulin-like growth factor 2 (somatomedin A)	Extracellular space	NM_010514	-2.547
<i>IGFBP6</i>	Insulin-like growth factor binding protein 6	Extracellular space	NM_008344	3.185
<i>IL1B</i>	Interleukin 1, β	Extracellular space	NM_008361	-2.457
<i>ITGA6</i>	Integrin, $\alpha 6$	Plasma membrane	AK045391	-2.360
<i>KITLG</i>	KIT ligand (includes EG:4254)	Extracellular space	NM_013598	-2.876
<i>LAMA3</i>	Laminin, $\alpha 3$	Extracellular space	XM_140451	2.272
<i>MAF</i>	v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)	Nucleus	NM_001025577	-2.254
<i>MAP2K7</i>	Mitogen-activated protein kinase kinase 7	Cytoplasm	BC070467	2.019
<i>MAP3K1</i>	Mitogen-activated protein kinase kinase kinase 1	Cytoplasm	NM_011945	-2.091
<i>MCL1</i>	Myeloid cell leukemia sequence 1 (BCL2-related)	Cytoplasm	NM_008562	-2.155
<i>NCOR1</i>	Nuclear receptor co-repressor 1	Nucleus	AK035813	-3.040
<i>NFATC2</i>	Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2	Nucleus	AK081853	-3.096
<i>NGFR</i>	Nerve growth factor receptor (TNFR superfamily, member 16)	Plasma membrane	NM_033217	3.110
<i>NOTCH1</i>	Notch homolog 1, translocation-associated (<i>Drosophila</i>)	Plasma membrane	NM_008714	-2.865
<i>NR1D1</i>	Nuclear receptor subfamily 1, group D, member 1	Nucleus	NM_145434	-2.275
<i>PKD1</i>	Polycystic kidney disease 1 (autosomal dominant)	Plasma membrane	NM_013630	2.086
<i>PTEN</i>	Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)	Cytoplasm	AK030750	-2.000
<i>PTPRC</i>	Pprotein tyrosine phosphatase, receptor type, C	Plasma membrane	NM_011210	-3.293
<i>RARB</i>	Retinoic acid receptor, β	Nucleus	NM_011243	4.876
<i>RARG</i>	Retinoic acid receptor, γ	Nucleus	NM_011244	2.050
<i>RGS3</i>	Regulator of G-protein signaling 3	Nucleus	NM_134257	2.091
<i>SLIT2</i>	Slit homolog 2 (<i>Drosophila</i>)	Extracellular space	AK038807	3.000
<i>STAT1</i>	Signal transducer and activator of transcription 1, 91 kDa	Nucleus	AK041814	-3.25
<i>TGFBR3</i>	Transforming growth factor, β receptor III	Plasma membrane	NM_011578	2.000
<i>THRB</i>	Thyroid hormone receptor, β [erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian]	Nucleus	NM_009380	2.947
<i>TNFRSF11B</i>	Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Plasma membrane	NM_008764	-3.978

Discussion

In this study, we focused on the therapeutic potential of MSCs in injured liver tissues. Using a microarray containing 44,000 genes, we assessed the gene expression profiles of MSCs in the presence of injured liver cells and normal liver cells. The results demonstrate that MSC gene responses to co-culturing with liver cells occurred in a condition-specific manner.

The results of the microarray analysis of MSCs co-cultured with normal liver cells demonstrate that genes associated with the inflammatory process were upregulated; e.g., CXCR6 (receptor for CXCL16), CCR3 (receptor for RANTES, MCP-2, -3, -4), IL-2, IL-11, CD34 and CD74 (Ii chain of class II MHC molecules). Although CXCR6 (5), IL-11 (6) and CD34 (7) were reportedly expressed in human MSCs, these genes were also upregulated in mice MSCs co-cultured with normal liver cells. It is also worth noting that the expression of CD74, an invariant chain of class II MHC molecules, was upregulated. CD74 is required for the macrophage migration inhibitory factor-induced activation of the extracellular signal-regulated kinase-1/2 MAP kinase cascade, cell proliferation and PGE₂ production (8). The procollagen (type 1 and α 1) gene was also upregulated and is believed to be associated with the tissue repair process. Neuregulin 4 is one of the neuregulins, a diverse family of EGF-like ligands that are sensitive to ADAM (a disintegrin and metalloproteinase) for the cleavage of the extracellular domain (9). Wnt signaling affects the developmental process of stem cells, including MSCs. In MSCs, signaling via the Wnt/ β -catenin pathway stimulates osteoblastogenesis and inhibits adipogenesis by regulating the relative levels of tissue-specific transcription factors (10). It has also been reported that the Wnt/ β -catenin pathway contributes to the activation of liver progenitor cells (11). Therefore, in MSCs co-cultured with normal liver cells, Wnt2 and catenin were also upregulated and may be associated with differentiation into hepatocytes.

The results of the microarray analysis of MSCs co-cultured with liver cells from CCl₄-injected mice demonstrate that genes associated with hypoxia response were upregulated; e.g., cytoglobin, hypoxia inducible factor 3 (α subunit) and erythropoietin. Cytoglobin, the gene involved in cell proliferation – possibly via collagen synthesis – and expressed predominantly in fibroblasts and associated cell types, is significantly elevated under hypoxic conditions (12). In this study, cytoglobin was upregulated in both the liver and CCl₄ liver groups. Hypoxia also induces the upregulation of erythropoietin, Sox6, and particularly Sox9, which is a key regulator of the differentiation of MSCs into chondrocytes. Another upregulated gene in the CCl₄ liver group was Vav2, the guanine nucleotide exchange factor. The primary function of this gene is the regulation of collagen phagocytosis, which is an α 2B1 integrin-dependent extracellular remodeling process (13). CXCL2 (Gro β) is a ligand of CXCR2 and contributes to the rapid mobilization of HSCs with enhanced engraftment properties (14). Upregulation of the v-Erb gene can be considered in the context of epidermal growth factor receptors. In particular, it is noticeable that the expression of hepatic nuclear factor 4 α , a critical transcription factor in hepatocyte differentiation (15), was upregulated.

MSCs co-cultured with liver cells from CCl₄-injected mice evidenced elevated levels of several growth factors, including epidermal growth factors. The observed up-regulation of frizzled homolog 4 reflects the possibility that the Wnt/ β -catenin pathway is relevant to the co-culturing of MSCs with liver cells.

Several genes were upregulated in common in the liver and CCl₄ liver groups; e.g., angiotensin receptor-like 1, CD34, procollagen type XXVII, cytochrome P450, fibroblast growth factor, forkhead box G1, hepatocyte nuclear factor 4, inhibitor of DNA binding 1, IL-1, matrix metalloproteinases, retinoic acid receptor β , S100 protein β , slit homologue 2 and tyrosine kinase 2. As well, several genes were downregulated in both groups; e.g., C3, CCR2, ADAM metalloproteinase with thrombospondin type 1 and 5, CD86, cullin 1, ErbB2 interacting protein, GNA13, hepatocyte growth factor, integrin α 6, NFATc2 and protein tyrosine phosphatase receptor type C. In the liver group, Socs3 was downregulated. Socs3 is a key inhibitor of cytokines that utilize gp130 (e.g., IL-23R and IL-6R), whereas Socs1 is believed to inhibit any cytokines that utilize γ c (16). In the CCl₄ liver group, PTEN was downregulated compared to the untreated MSCs. PTEN is a tumor suppressor gene and functions as a lipid phosphatase that decreases the PI3K signaling pathway. In the absence of PTEN, HSCs are driven into the cell cycle; the loss of PTEN frequently promotes the formation of a variety of tumors (17).

In summary, MSCs co-cultured with normal liver cells exhibited the potential for differentiation into functional liver cells via upregulation of the genes associated with inflammatory response. MSCs co-cultured with CCl₄ liver cells differentiated into functional liver cells and upregulated genes related to hypoxic stress. In the CCl₄-injected mice, hypoxic-induced responses were involved in the regeneration process of liver cells via MSCs. We suggest that a diverse repairing pathway contributes to the regeneration process of liver cells by MSCs.

Acknowledgements

This work was supported by a Korea Research Foundation Grant funded by the Korean government (KOEHRD, Basic Research Promotion Fund) (KRF-2007-531-E00061).

References

1. Lange C, Bruns H, Kluth D, Zander AR and Fiegel HC: Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells. *World J Gastroenterol* 12: 2394-2397, 2006.
2. Ong SY, Dai H and Leong KW: Hepatic differentiation potential of commercially available human mesenchymal stem cells. *Tissue Eng* 12: 3477-3485, 2006.
3. Talens-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV and Gomez-Lechon MJ: Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. *World J Gastroenterol* 12: 5834-5845, 2006.
4. Jung YJ, Ryu KH, Cho SJ, Woo SY, Seoh JY, Chun CH, Yoo K, Moon IH and Han HS: Syngenic bone marrow cells restore hepatic function in carbon tetrachloride-induced mouse liver injury. *Stem Cells Dev* 15: 687-695, 2006.
5. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM and Silberstein LE: Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. *Stem Cells* 24: 1030-1041, 2006.

6. Majumdar MK, Thiede MA, Mosca JD, Moorman M and Gerson SL: Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. *J Cell Physiol* 176: 57-66, 1998.
7. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W and Ho AD: Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol* 33: 1402-1416, 2005.
8. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA and Bucala R: MIF signal transduction initiated by binding to CD74. *J Exp Med* 197: 1467-476, 2003.
9. Hayes NV and Gullick WJ: The neuregulin family of genes and their multiple splice variants in breast cancer. *J Mammary Gland Biol Neoplasia* 13: 205-214, 2008.
10. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD and MacDougald OA: Regulation of osteoblastogenesis and bone mass by Wnt10b. *Proc Natl Acad Sci USA* 102: 3324-3329, 2005.
11. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, Chen C, Liu SQ, Wu MC and Wang HY: Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. *Cancer Res* 68: 4287-4295, 2008.
12. Burmester T, Gerlach F and Hankeln T: Regulation and role of neuroglobin and cytoglobin under hypoxia. *Adv Exp Med Biol* 618: 169-180, 2007.
13. Arora PD, Marignani P and McCulloch CA: Collagen phagocytosis is regulated by the guanine nucleotide exchange factor Vav2. *Am J Physiol Cell Physiol* 295: C130-C137, 2008.
14. Pelus LM and Fukuda S: Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. *Exp Hematol* 34: 1010-1020, 2006.
15. Kymrzi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ and Talianidis I: Plasticity and expanding complexity of the hepatic transcription factor network during liver development. *Genes Dev* 20: 2293-2305, 2006.
16. O'Shea JJ and Murray PJ: Cytokine signaling modules in inflammatory responses. *Immunity* 28: 477-487, 2008.
17. Rossi DJ and Weissman IL: Pten, tumorigenesis, and stem cell self-renewal. *Cell* 125: 229-231, 2006.

